Zyla Life Sciences

US suitability petitions may be seeing renewed interest from sponsors following a surge of filings after the introduction of goal dates in October and then a drop-off of submissions after that. Nimish

Goal dates and enhanced regulatory review processes appear to have invigorated sponsors, including leading Indian pharma firms, to file or refile suitability petitions in the US, reviving a strategic

US suitability petitions may be seeing renewed interest from sponsors following a surge of filings after the introduction of goal dates in October and then a drop-off of submissions after that. Nimish

Purdue Pharma LP has submitted all required post-marketing studies on the real-world use of OxyContin (extended-release oxycodone) to the US Food and Drug Administration and the data are once again u